FNY Investment Advisers LLC bought a new stake in CareDx, Inc (NASDAQ:CDNA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 5,000 shares of the company’s stock, valued at approximately $316,000.
Other hedge funds also recently modified their holdings of the company. Berman Capital Advisors LLC boosted its stake in CareDx by 82.0% in the second quarter. Berman Capital Advisors LLC now owns 304 shares of the company’s stock valued at $27,000 after acquiring an additional 137 shares during the period. Captrust Financial Advisors acquired a new position in CareDx in the first quarter valued at approximately $48,000. Advisory Services Network LLC acquired a new position in CareDx in the second quarter valued at approximately $58,000. Cresset Asset Management LLC acquired a new position in CareDx in the second quarter valued at approximately $202,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of CareDx during the first quarter worth approximately $204,000.
In other CareDx news, insider Reginald Seeto sold 658 shares of the company’s stock in a transaction on Friday, August 27th. The stock was sold at an average price of $80.00, for a total value of $52,640.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter Maag sold 10,000 shares of the company’s stock in a transaction on Friday, November 5th. The shares were sold at an average price of $49.40, for a total value of $494,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,658 shares of company stock worth $1,985,160. 4.60% of the stock is owned by corporate insiders.
CareDx (NASDAQ:CDNA) last announced its earnings results on Thursday, October 28th. The company reported $0.07 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.21. CareDx had a negative return on equity of 4.24% and a negative net margin of 6.54%. The firm had revenue of $75.60 million for the quarter, compared to analysts’ expectations of $74.11 million. During the same quarter in the previous year, the company earned ($0.06) earnings per share. The firm’s quarterly revenue was up 41.6% compared to the same quarter last year. On average, equities analysts predict that CareDx, Inc will post -0.47 earnings per share for the current fiscal year.
Several equities analysts have recently issued reports on the company. Raymond James reduced their price objective on CareDx from $108.00 to $90.00 and set a “strong-buy” rating for the company in a research report on Friday, October 29th. Piper Sandler boosted their price objective on CareDx from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Friday, July 30th. BTIG Research reiterated a “buy” rating and set a $99.00 price objective on shares of CareDx in a research report on Friday, October 29th. Finally, Zacks Investment Research downgraded CareDx from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $97.60.
CareDx Company Profile
CareDx, Inc operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its product includes AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in South San Francisco, CA.
Recommended Story: dividend yield calculator
Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc (NASDAQ:CDNA).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.